Current landscape of phosphodiesterase 10A (PDE10A) inhibition

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7299-7331

  Chappie, Thomas A ^a   Helal, Christopher J ^a   Hou, Xinjun ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; CLOZAPINE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ESTERASE; ESTERASE INHIBITOR; GLUCOSE; HALOPERIDOL; MONOCROTALINE; NEUROLEPTIC AGENT; PAPAVERINE; PHENCYCLIDINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE 10A1; PHOSPHODIESTERASE 10A2; PHOSPHODIESTERASE INHIBITOR; PQ 10; RISPERIDONE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

ALLOSTERISM; BASAL GANGLION; BEHAVIOR; BRAIN; CATALYSIS; CORPUS STRIATUM; CRYSTAL STRUCTURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; GLUCOSE METABOLISM; HABENULA; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; NONHUMAN; OPTIMAL DRUG DOSE; PAIRED PULSE INHIBITION; PREPULSE INHIBITION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC AMP; CYCLIC GMP; HUMANS; HYDROLYSIS; MICE; MODELS, MOLECULAR; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; RATS;

EID: 84866336121     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3004976     Document Type: Review

References (101)

1. Loughney, K.; Snyder, P. B.; Uher, L.; Rosman, G. J.; Ferguson, K.; Florio, V. A. Isolation and characterization of PDE10A, a novel human 3′,5′-cyclic nucleotide phosphodiesterase Gene 1999, 234, 109-117 (Pubitemid 29294097)
2. Fujishige, K.; Kotera, J.; Omori, K. Striatum- and testis-specific phosphodiesterase PDE10A Eur. J. Biochem. 1999, 266, 1118-1127
3. Fujishige, K.; Kotera, J.; Michibata, H.; Yuasa, K.; Takebayashi, S.; Okumura, K.; Omori, K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A) J. Biol. Chem. 1999, 274, 18438-18445
4. Soderling, S. H.; Bayuga, S. J.; Beavo, J. A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7071-7076 (Pubitemid 29275011)
5. Adamowicz, W.; Bove, S.; Romegialli, A.; Mariga, A.; Kleiman, R. In Society for Neuroscience; San Diego, CA, 2010.
6. Lakics, V.; Karran, E. H.; Boess, F. G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues Neuropharmacology 2010, 59, 367-374
7. Seeger, T. F.; Bartlett, B.; Coskran, T. M.; Culp, J. S.; James, L. C.; Krull, D. L.; Lanfear, J.; Ryan, A. M.; Schmidt, C. J.; Strick, C. A.; Varghese, A. H.; Williams, R. D.; Wylie, P. G.; Menniti, F. S. Immunohistochemical localization of PDE10A in the rat brain Brain Res. 2003, 985, 113-126 (Pubitemid 37088176)
8. Coskran, T. M.; Morton, D.; Menniti, F. S.; Adamowicz, W. O.; Kleiman, R. J.; Ryan, A. M.; Strick, C. A.; Schmidt, C. J.; Stephenson, D. T. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species J. Histochem. Cytochem. 2006, 54, 1205-1213 (Pubitemid 44623341)
9. Kotera, J.; Fujishige, K.; Yuasa, K.; Omori, K. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP Biochem. Biophys. Res. Commun. 1999, 261, 551-557 (Pubitemid 29408096)
10. Kotera, J.; Sasaki, T.; Kobayashi, T.; Fujishige, K.; Yamashita, Y.; Omori, K. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation J. Biol. Chem. 2004, 279, 4366-4375 (Pubitemid 38199025)
11. Charych, E. I.; Jiang, L.-X.; Lo, F.; Sullivan, K.; Brandon, N. J. Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia J. Neurosci. 2010, 30, 9027-9037
12. Matthiesen, K.; Nielsen, J. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity Biochem. J. 2009, 423, 401-409
13. Heikaus, C. C.; Pandit, J.; Klevit, R. E. Cyclic Nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights Structure 2009, 17, 1551-1557
14. Schmidt, C. J.; Chapin, D. S.; Cianfrogna, J.; Corman, M. L.; Hajos, M.; Harms, J. F.; Hoffman, W. E.; Lebel, L. A.; McCarthy, S. A.; Nelson, F. R.; Proulx-LaFrance, C.; Majchrzak, M. J.; Ramirez, A. D.; Schmidt, K.; Seymour, P. A.; Siuciak, J. A.; Tingley, F. D., III; Williams, R. D.; Verhoest, P. R.; Menniti, F. S. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia J. Pharmacol. Exp. Ther. 2008, 325, 681-690 (Pubitemid 351574819)
15. Clineschmidt, B. V.; Martin, G. E.; Bunting, P. R. Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5 H -dibenzo[ a, d ]cyclohepten-5,10- imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties Drug Dev. Res. 1982, 2, 123-134 (Pubitemid 12116862)
16. Clineschmidt, B. V.; Martin, G. E.; Bunting, P. R.; Papp, N. L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5 H -dibenzo[ a, d ]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties Drug Dev. Res. 1982, 2, 135-145 (Pubitemid 12107825)
17. Höfgen, N.; Stange, H.; Schindler, R.; Lankau, H.-J.; Grunwald, C.; Langen, B.; Egerland, U.; Tremmel, P.; Pangalos, M. N.; Marquis, K. L.; Hage, T.; Harrison, B. L.; Malamas, M. S.; Brandon, N. J.; Kronbach, T. Discovery of imidazo[1,5- a ]pyrido[3,2- e ]pyrazines as a new class of phosphodiesterase 10A inhibitiors J. Med. Chem. 2010, 53, 4399-4411
18. Iorio, L. C.; Barnett, A.; Leitz, F. H.; Houser, V. P.; Korduba, C. A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems J. Pharmacol. Exp. Ther. 1983, 226, 462-468 (Pubitemid 13041523)
19. Chappie, T.; Humphrey, J.; Menniti, F.; Schmidt, C. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape Curr. Opin. Drug Discovery Dev. 2009, 12, 458-467
20. Verhoest, P. R.; Chapin, D. S.; Corman, M.; Fonseca, K.; Harms, J. F.; Hou, X.; Marr, E. S.; Menniti, F. S.; Nelson, F.; O'Connor, R.; Pandit, J.; Proulx-LaFrance, C.; Schmidt, A. W.; Schmidt, C. J.; Suiciak, J. A.; Liras, S. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1 H -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia J. Med. Chem. 2009, 52, 5188-5196
21. Dedeurwaerdere, S.; Wintmolders, C.; Vanhoof, G.; Langlois, X. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker J. Pharmacol. Exp. Ther. 2011, 339, 210-217
22. Steulet, A. F.; Bernasconi, R.; Leonhardt, T.; Martin, P.; Grunenwald, C.; Bischoff, S.; Heinrich, M.; Bandelier, V.; Maitre, L. Effects of selective dopamine D1 and D2 receptor agonists on the rate of GABA synthesis in mouse brain Eur. J. Pharmacol. 1990, 191, 19-27 (Pubitemid 20386121)
23. Pfeiffer, F. R.; Wilson, J. W.; Weinstock, J.; Kuo, G. Y.; Chambers, P. A.; Holden, K. G.; Hahn, R. A.; Wardell, J. R.; Alfonso, J. T. Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1 H -3-benzazepines J. Med. Chem. 1982, 25, 352-358 (Pubitemid 12078634)
24. Merck, G. Preliminary notice of a new organic base in opium Justus Liebigs Ann. Chem. 1848, 66, 125-128
25. Chappie, T. A.; Humphrey, J. M.; Allen, M. P.; Estep, K. G.; Fox, C. B.; Lebel, L. A.; Liras, S.; Marr, E. S.; Menniti, F. S.; Pandit, J.; Schmidt, C. J.; Tu, M.; Williams, R. D.; Yang, F. V. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors J. Med. Chem. 2007, 50, 182-185 (Pubitemid 46147698)
26. Kleiman, R. J.; Kimmel, L. H.; Bove, S. E.; Lanz, T. A.; Harms, J. F.; Romegialli, A.; Miller, K. S.; Willis, A.; des Etages, S.; Kuhn, M.; Schmidt, C. J. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease J. Pharmacol. Exp. Ther. 2011, 336, 64-76
27. Giampà, C.; Laurenti, D.; Anzilotti, S.; Bernardi, G.; Menniti, F. S.; Fusco, F. R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease PLoS ONE 2010, 5, e13417
28. Tian, X.; Vroom, C.; Ghofrani, H. A.; Weissmann, N.; Bieniek, E.; Grimminger, F.; Seeger, W.; Schermuly, R. T.; Pullamsetti, S. S. Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling PLoS ONE 2011, 6, e18136
29. Sweet, L. PDE10a Inhibitors for Treating Diabetes and Related Disorders. WO2005012485A2, 2005; 28 pp.
30. Schuit, F. Phosphodiesterase 10A Inhibitors To Amplify the Action of GLP-1-Mimetics or DPP-IV Inhibitors in Diabetes. WO2005120474A2, 2005; 25 pp.
31. Black, S. C.; Gibbs, E. M. Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions. WO2005120514A1, 2005; 47 pp.
32. Pandit, J. Crystal Structure of Catalytic Domain of Rat 3′,5′-Cyclic Nucleotide Phosphodiesterase (PDE10A) Inhibitor Complex and Uses in the Discovery of Psychotherapeutic Drugs. US2005202550A1, 2005; 72 pp.
33. Helal, C. J.; Kang, Z.; Hou, X.; Pandit, J.; Chappie, T. A.; Humphrey, J. M.; Marr, E. S.; Fennell, K. F.; Chenard, L. K.; Fox, C.; Schmidt, C. J.; Williams, R. D.; Chapin, D. S.; Siuciak, J.; Lebel, L.; Menniti, F.; Cianfrogna, J.; Fonseca, K. R.; Nelson, F. R.; O'Connor, R.; MacDougall, M.; McDowell, L.; Liras, S. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia J. Med. Chem. 2011, 54, 4536-4547
34. Day, J. P.; Lindsay, B.; Riddell, T.; Jiang, Z.; Allcock, R. W.; Abraham, A.; Sookup, S.; Christian, F.; Bogum, J.; Martin, E. K.; Rae, R. L.; Anthony, D.; Rosair, G. M.; Houslay, D. M.; Huston, E.; Baillie, G. S.; Klussmann, E.; Houslay, M. D.; Adams, D. R. Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4) J. Med. Chem. 2011, 54, 3331-3347
35. Wang, H.; Liu, Y.; Hou, J.; Zheng, M.; Robinson, H.; Ke, H. Structural insight into substrate specificity of phosphodiesterase 10 Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5782-5787 (Pubitemid 47175611)
36. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
37. Lebel, L. A.; Menniti, F. S.; Schmidt, C. J. Therapeutic use of selective PDE10A inhibitors. US2003/0032579 A1, 2003; 20 pp.
38. Siuciak, J. A.; Chapin, D. S.; Harms, J. F.; Lebel, L. A.; McCarthy, S. A.; Chambers, L.; Shrikhande, A.; Wong, S.; Menniti, F. S.; Schmidt, C. J. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis Neuropharmacology 2006, 51, 386-396 (Pubitemid 44061894)
39. Kehler, J.; Kilburn, J. P. Patented PDE10A inhibitors: novel compounds since 2007 Expert Opin. Ther. Pat. 2009, 19, 1715-1725
40. Allen, J. R.; Biswas, K.; Chavez, F., Jr.; Chen, N.; Demorin, F. F.; Falsey, J. R.; Frohn, M.; Harrington, P.; Horne, D.; Hu, E.; Kaller, M. R.; Kunz, R.; Monenschein, H.; Nguyen, T.; Pickrell, A.; Reichelt, A.; Rumfelt, S.; Rzasa, R.; Sham, K.; Yao, G. Pyridine and Pyrimidine Derivatives as Phosphodiesterase 10 Inhibitors. WO2010057126A1, 2010; 396 pp.
41. Allen, J. R.; Bourbeau, M. P.; Chen, N.; Hu, E.; Kunz, R.; Rumfelt, S. Pyrazine Compounds as Phosphodiesterase 10 Inhibitors and Their Preparation and Use in the Treatment of Diseases. WO2010057121A1, 2010; 321 pp.
42. Allen, J. R.; Chen, N.; Falsey, J. R.; Frohn, M.; Harrington, P.; Hu, E.; Kaller, M. R.; Kunz, R.; Mercede, S. J.; Nguyen, T. T.; Pickrell, A. J.; Reichelt, A.; Rumfelt, S.; Rzasa, R. M.; Sham, K.; Siegmund, A. C.; Tegley, C. M.; Yao, G. Aminopyridine, Carboxypyridine, Pyrimidine and Pyrazine Compounds as Phosphodiesterase 10 Inhibitors and Their Preparation and Use in the Treatment of PDE10-Mediated Diseases. US20100160280A1, 2010; 268 pp.
43. Allen, J.; Frohn, M.; Harrington, P.; Pickrell, A.; Rzasa, R.; Sham, K.; Hu, E. Heteroaryloxycarbocyclyl Compounds as PDE10 Inhibitors and Their Preparation and Use in the Treatment of Diseases. WO2011143366A1, 2011; 178 pp.
44. Allen, J.; Horne, D. B.; Hu, E.; Kaller, M. R.; Monenschein, H.; Nguyen, T. T.; Reichelt, A.; Rzasa, R. M. Preparation of Heteroaryloxyheterocyclyl and Heteroarylaminoheterocyclyl Compounds as Phosphodiesterase 10 (PDE10) Inhibitors. WO2011143495A1, 2011; 394 pp.
45. Allen, J. R.; Andrews, K. L.; Frohn, M. J.; Harrington, P. E.; Pickrell, A. J.; Rzasa, R. M. Preparation of Nitrogen-Containing Heterocyclic Compounds as Phosphodiesterase 10 Inhibitors. WO2011143129A1, 2011; 117 pp.
46. Allen, J. R.; Chen, J. J.; Frohn, M. J.; Hu, E.; Liu, Q.; Pickrell, A. J.; Rumfelt, S.; Rzasa, R. M.; Zhong, W. Preparation of Nitrogen Heterocyclic Compounds Useful as 3′,5′-Cyclic Nucleotide-Specific Phosphodiesterase 10 (PDE10) Inhibitors. WO2011143365A1, 2011; 525 pp.
47. Stange, H.; Langen, B.; Egerland, U.; Hoefgen, N.; Priebs, M.; Malamas, M. S.; Erdei, J. J.; Ni, Y. Preparation of Imidazo[5,1- c ][1,2,4]benzotriazine Derivatives as Inhibitors of Phosphodiesterases. WO2010054260A1, 2010; 183 pp.
48. Schmidt, C. J. Phosphodiesterase inhibitors as potential cognition enhancing agents Curr. Top. Med. Chem. 2010, 10, 222-230
49. Ripka, A.; Shapiro, G.; Chesworth, R. 1,2-Disubstituted Heterocyclic Compounds as Phosphodiesterase 10 Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of CNS Disorders and Disorders Affected by CNS Function. WO2009158393A1, 2009; 228 pp.
50. Chesworth, R.; Shapiro, G.; Ripka, A. Di-Substituted Phenyl Compounds as Phosphodiesterase 10 Inhibitors and Their Preparation Useful in the Treatment of CNS Disorders and Disorders Affected by CNS Function. WO2009158467A2, 2009; 210 pp.
51. Ripka, A.; Shapiro, G.; Chesworth, R. 5- and 6-Membered Heterocyclic Compounds as Phosphodiesterase Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of CNS Disorders and Disorders Affected by CNS Function. WO2009158473A1, 2009; 172 pp.
52. Ripka, A.; Shapiro, G.; Chesworth, R. Preparation of Vicinal Substituted Cyclopropyl Compounds as PDE-10 Inhibitors. WO2010006130A2, 2010; 70 pp.
53. Gharat, L. A.; Narayana, L.; Yadav, P. S.; Khairatkar-Joshi, N.; Bajpai, M. Preparation of Heteroaryl Compounds as PDE10A Inhibitors. WO2011132048A1, 2011; 92 pp.
54. Gharat, L. A.; Gajera, J. M.; Khairatkar-Joshi, N.; Bajpai, M. Tricycle Compounds as Phosphodiesterase-10 Inhibitors and Their Preparation. WO2011132051A2, 2011; 177 pp.
55. Card, G. L.; England, B. P.; Suzuki, Y.; Fong, D.; Powell, B.; Lee, B.; Luu, C.; Tabrizizad, M.; Gillette, S.; Ibrahim, P. N.; Artis, D. R.; Bollag, G.; Milburn, M. V.; Kim, S.-H.; Schlessinger, J.; Zhang, K. Y. J. Structural Basis for the Activity of Drugs That Inhibit Phosphodiesterases Structure (Cambridge, MA, U. S.) 2004, 12, 2233-2247 (Pubitemid 39593200)
56. Huai, Q.; Wang, H.; Sun, Y.; Kim, H.-Y.; Liu, Y.; Ke, H. Three-Dimensional Structures of PDE4D in Complex with Roliprams and Implication on Inhibitor Selectivity Structure (Cambridge, MA, U. S.) 2003, 11, 865-873 (Pubitemid 36833272)
57. Xu, R. X.; Rocque, W. J.; Lambert, M. H.; Vanderwall, D. E.; Luther, M. A.; Nolte, R. T. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram J. Mol. Biol. 2004, 337, 355-365 (Pubitemid 38293404)
58. Lingam, P. R. V. S.; Thomas, A.; Khairatkar-Joshi, N.; Bajpai, M.; Gullapalli, S.; Dahale, D. H.; Mindhe, A. S.; Rathi, V. E. Preparation of Aryl Substituted Olefinic Compounds as Phosphodiesterase 10A (PDE10A) Inhibitors. WO2011138657A1, 2011; 204 pp.
59. Alberati, D.; Gobbi, L.; Koerner, M.; Kuhn, B.; Peters, J.-U.; Rodriguez, S. R. M.; Rogers-Evans, M.; Rudolph, M. Preparation of Pyridazinone Derivatives as PDE10A Inhibitors. WO2010063610A1, 2010; 245 pp.
60. Alberati, D.; Koerner, M.; Kuhn, B.; Peters, J.-U.; Rodriguez, S. R. M.; Rogers-Evans, M.; Rudolph, M. Preparation of Heteroaryl Substituted Pyridazinone Derivatives as PDE10A Inhibitors. WO2010094762A1, 2010; 95 pp.
61. Alberati, D.; Alvarez, S. R.; Bleicher, K.; Flohr, A.; Groebke, Z. K.; Koerner, M.; Kuhn, B.; Peters, J.-U.; Rudolph, M. Novel Imidazopyridines as PDE10A Inhibitors and Their Preparation and Use in the Treatment of Central Nervous System Diseases. US20110071128A1, 2011; 39 pp.
62. Bleicher, K.; Flohr, A.; Groebke, Z. K.; Koerner, M.; Kuhn, B.; Peters, J.-U.; Rodriguez, S. R. M.; Vieira, E. Preparation of Azaheteroaryl Derivatives for Use as PDE10A Inhibitors. WO2011089132A1, 2011; 118 pp.
63. Bleicher, K.; Flohr, A.; Groebke, Z. K.; Gruber, F.; Koerner, M.; Kuhn, B.; Peters, J.-U.; Rodriguez, S. R. M. Nitrogen Containing Heteroaryl Compounds as PDE10A Inhibitors and Their Preparation and Use in the Treatment of Diseases. WO2011154327A1, 2011; 372 pp.
64. Pastor-Fernandez, J.; Bartolome-Nebreda, J. M.; MacDonald, G. J.; Conde-Ceide, S.; Delgado-Gonzalez, O.; Vanhoof, G. C. P.; Van, G. M. L. M.; Martin-Martin, M. L.; Alonso-De, D. S.-A. Imidazo[1,2- b ]pyridazine Derivatives as PDE10 Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of CNS Diseases. WO2011051342A1, 2011; 166 pp.
65. Bartolome-Nebreda, J. M.; Conde-Ceide, S.; MacDonald, G. J.; Pastor-Fernandez, J.; Van, G. M. L. M.; Martin-Martin, M. L.; Vanhoof, G. C. P. Preparation of Imidazo[1,2- a ]pyrazine Derivatives and Their Use for the Prevention or Treatment of Neurological, Psychiatric and Metabolic Disorders and Diseases. WO2011110545A1, 2011; 169 pp.
66. Asproni, B.; Murineddu, G.; Pau, A.; Pinna, G. A.; Langgård, M.; Christoffersen, C. T.; Nielsen, J.; Kehler, J. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5- c ]quinazolines as potent phosphodiesterase 10A inhibitors Bioorg. Med. Chem. 2011, 19, 642-649
67. Kehler, J.; Ritzen, A.; Langgård, M.; Petersen, S. L.; Farah, M. M.; Bundgaard, C.; Christoffersen, C. T.; Nielsen, J.; Kilburn, J. P. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3738-3742
68. Ritzen, A.; Kehler, J.; Langgaard, M.; Nielsen, J.; Kilburn, J. P.; Farah, M. M. Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors for Treating Neurodegenerative Disorder, Psychiatric Disorder, or Drug Addiction. WO2009152825A1, 2009; 91 pp.
69. Ritzen, A.; Kehler, J.; Langgaard, M.; Nielsen, J.; Kilburn, J. P.; Farah, M. M. Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors for Treating Neurodegenerative Disorder, Psychiatric Disorder, or Drug Addiction. US20100016303A1, 2010; 34 pp.
70. Pueschl, A.; Nielsen, J.; Kehler, J.; Kilburn, J. P.; Marigo, M.; Langgaard, M. Preparation of Heteroaromatic Aryl Triazole Derivatives as PDE10A Enzyme Inhibitors for Treating Neurodegenerative Disorders, Psychiatric Disorders, or Drug Addiction. WO2011072697A1, 2011; 68 pp.
71. Pueschl, A.; Nielsen, J.; Kehler, J.; Kilburn, J. P.; Marigo, M.; Langgaard, M. Preparation of 2-Arylimidazole Derivatives as PDE10A Enzyme Inhibitors for Treating Neurodegenerative Disorders, Psychiatric Disorders, and Drug Addiction. WO2011072696A1, 2011; 62 pp.
72. Pueschl, A.; Nielsen, J.; Kehler, J.; Kilburn, J. P.; Marigo, M.; Langgaard, M. Phenylimidazole Derivatives Comprising an Ethynylene Linker as Phosphodiesterase 10A Enzyme Inhibitors. WO2011072695A1, 2011; 48 pp.
73. Breslin, M. J.; Coleman, P. J.; Cox, C. D.; Raheem, I. T.; Schreier, J. D. Preparation of Alkoxy-tetrahydro-pyridopyrimidine PDE10 Inhibitors. WO2010138430A1, 2010; 70 pp.
74. Hostetler, E.; Cox, C. D.; Fan, H. Radiolabeled PDE10 Inhibitors. WO2010138577A1, 2010; 71 pp.
75. Cox, C. D.; Bunda, J. L.; Flores, B. A.; Shipe, W. Pyrimidinones as Phosphodiesterase 10 Inhibitors for the Treatment of Central Nervous System Disorders. WO2010138585A1, 2010; 68 pp.
76. Breslin, M. J.; Coleman, P. J.; Cox, C. D.; Raheem, I. T.; Schreier, J. D. Preparation of Aminotetrahydropyridopyrimidine Derivatives for Use as PDE10 Inhibitors. WO2011022213A1, 2011; 48 pp.
77. Breslin, M. J.; Cox, C. D.; Raheem, I. T. Aryl Aminopyridine Phosphodiesterase 10 Inhibitors for Treatment of Central Nervous System Disorders. WO2011053559A1, 2011; 47 pp.
78. Cox, C. D.; Raheem, I. T.; Flores, B. A.; Whitman, D. B. 7-Aza-quinazolines as PDE10 Inhibitors. US20110319409A1, 2011; 23 pp.
79. Morimoto, H.; Sakamoto, T.; Himiyama, T.; Kawanishi, E.; Matsumura, T. Preparation of Substituted Pyrimidine Derivatives for Use as PDE10 Inhibitors. WO2010030027A1, 2010; 117 pp.
80. Kawanishi, E.; Matsumura, T. Preparation of Trisubstituted Pyrimidines as Phosphodiesterase PDE10 Inhibitors. WO2010027097A1, 2010; 85 pp.
81. Kawanishi, E.; Hongu, M.; Tanaka, Y. Preparation of Pyrazolopyrimidine Compounds and Their Use as Therapeutic PDE10 Inhibitors. WO2011105628A1, 2011; 139 pp.
82. Gage, J. L.; Onrust, R.; Johnston, D.; Osnowski, A.; MacDonald, W.; Mitchell, L.; Ürögdi, L.; Rohde, A.; Harbol, K.; Gragerov, S.; Dormán, G.; Wheeler, T.; Florio, V.; Cutshall, N. S. N -Acylhydrazones as inhibitors of PDE10A Bioorg. Med. Chem. Lett. 2011, 21, 4155-4159
83. Cutshall, N. S.; Gage, J. L.; Wheeler, T. N.; Little, T. L. Preparation of Phenylfuranylheteroarylphenylethanone Derivatives and Analogs for Use as PDE10 Inhibitors. WO2011112828A1, 2011; 140 pp.
84. Ho, G. D.; Yang, S.-W.; Smith, E. M.; McElroy, W. T.; Basu, K.; Smotryski, J.; Tan, Z.; McKittrick, B. A.; Tulshian, D. B. Preparation of Substituted Pyrazoloquinolines and Derivatives Thereof. WO2010062559A1, 2010; 129 pp.
85. Yang, S.-W.; Smotryski, J.; McElroy, W. T.; Tan, Z.; Ho, G.; Tulshian, D.; Greenlee, W. J.; Guzzi, M.; Zhang, X.; Mullins, D.; Xiao, L.; Hruza, A.; Chan, T.-M.; Rindgen, D.; Bleickardt, C.; Hodgson, R. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia Bioorg. Med. Chem. Lett. 2012, 22, 235-239
86. Ho, G. D.; Smith, E. M.; Kiselgof, E. Y.; Basu, K.; Tan, Z.; McKittrick, B.; Tulshian, D. Preparation of Substituted Triazolopyridines and Analogs as Phosphodiesterase 10 (PDE10) Inhibitors. WO2010117926A1, 2010; 59 pp.
87. Ho, G. D.; Seganish, W. M.; Tulshian, D. B.; Timmers, C. M.; Rijn, R. D. V.; Loozen, H. J. J. 5,6-Dihydroimidazo[5,1- a ]isoquinoline Derivatives as PDE10 Inhibitors and Their Preparation and Use for the Treatment of PDE10-Modulated Diseases. WO2011008597A1, 2011; 50 pp.
88. Campbell, J. E.; Hewitt, M. C.; Jones, P.; Xie, L. Preparation of Heteroaryl Compounds Useful in the Treatment of CNS, Metabolic and Other Diseases. WO2011150156A2, 2011; 233 pp.
89. Taniguchi, T.; Kawada, A.; Kondo, M.; Quinn, J. F.; Kunitomo, J.; Yoshikawa, M.; Fushimi, M. Preparation of Pyridazinone Compounds as Phosphodiesterase 10A Inhibitors for Preventing and Treating Schizophrenia. US20100197651A1, 2010; 175 pp.
90. Taniguchi, T.; Yoshikawa, M.; Miura, K.; Hasui, T.; Honda, E.; Imamura, K.; Kamata, M.; Kamisaki, H.; Quinn, J. F.; Raker, J.; Camara, F.; Wang, Y. Preparation of Fused Heterocyclic Compounds as Phosphodiesterase 10A Inhibitors for Preventing and Treating Schizophrenia. WO2011163355A1, 2011; 386 pp.
91. Grimwood, S.; Hartig, P. R. Target site occupancy: emerging generalizations from clinical and preclinical studies Pharmacol. Ther. 2009, 122, 281-301
92. Celen, S.; Koole, M.; De Angelis, M.; Sannen, I.; Chitneni, S. K.; Alcazar, J.; Dedeurwaerdere, S.; Moechars, D.; Schmidt, M.; Verbruggen, A.; Langlois, X.; Van Laere, K.; Andrés, J. I.; Bormans, G. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain J. Nucl. Med. 2010, 51, 1584-1591
93. Andrés, J.-I.; De Angelis, M.; Alcázar, J.; Iturrino, L.; Langlois, X.; Dedeurwaerdere, S.; Lenaerts, I.; Vanhoof, G.; Celen, S.; Bormans, G. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging J. Med. Chem. 2011, 54, 5820-5835
94. Andres-Gil, J. I.; De, A. M.; Bormans, G. M. R.; Celen, S. J. L. Radiolabelled PDE10 Ligands. WO2011051324A1, 2011; 72 pp.
95. 11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain Bioorg. Med. Chem. 2011, 19, 1666-1673
96. Chen, Y.; Spangler, W.; Kreulen, J.; Presented at IEEE International Conference on Data Mining (ICDM), 2009.
97. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449
98. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 1996, 39, 2887-2893 (Pubitemid 26251026)
99. Medina-Franco, J. L.; Martinez-Mayorga, K.; Giulianotti, M. A.; Houghten, R. A.; Pinilla, C. Principal component analysis Curr. Comput.-Aided Drug Des 2008, 4, 322-333
100. Accelrys, Inc., San Diego, CA, U.S.
101. TIBCO Software, Inc. Somerville, MA, U.S.